Natasha Kyprianou Selected Research

Quinazolines

8/2020	Repurposing of α1-Adrenoceptor Antagonists: Impact in Renal Cancer.
1/2019	Predictive and targeting value of IGFBP-3 in therapeutically resistant prostate cancer.
1/2019	Impact of α-adrenoceptor antagonists on prostate cancer development, progression and prevention.
10/2017	Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells.
1/2014	Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells.
11/2013	Therapeutic value of quinazoline-based compounds in prostate cancer.
12/2011	Advances in the design and synthesis of prazosin derivatives over the last ten years.
5/2011	Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma.
12/2009	Apoptosis induction by doxazosin and other quinazoline alpha1-adrenoceptor antagonists: a new mechanism for cancer treatment?
1/2008	Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Natasha Kyprianou Research Topics

Disease

86	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2002
84	Neoplasms (Cancer) 01/2022 - 01/2002
25	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2005
7	Urinary Bladder Neoplasms (Bladder Cancer) 10/2020 - 05/2005
7	Carcinogenesis 01/2017 - 12/2007
6	COVID-19 01/2021 - 01/2020
4	Renal Cell Carcinoma (Grawitz Tumor) 11/2021 - 01/2015
4	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2019 - 05/2002
4	Hypertension (High Blood Pressure) 01/2019 - 01/2002
3	Virus Diseases (Viral Diseases) 10/2020 - 09/2020
3	Kidney Neoplasms (Kidney Cancer) 08/2020 - 05/2011
3	Carcinoma (Carcinomatosis) 01/2020 - 07/2013
2	Inflammation (Inflammations) 10/2020 - 09/2009
2	Disease Progression 10/2020 - 03/2012
2	Breast Neoplasms (Breast Cancer) 08/2009 - 09/2004
2	Hyperplasia 01/2008 - 01/2002
1	Testicular Neoplasms (Testicular Cancer) 10/2020
1	Urologic Neoplasms (Urological Cancer) 08/2020
1	Lymphatic Metastasis 01/2019

Drug/Important Bio-Agent (IBA)

35	AndrogensIBA 09/2020 - 01/2002
21	QuinazolinesIBA 08/2020 - 01/2002
17	Androgen Receptors (Androgen Receptor)IBA 01/2020 - 02/2008
16	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2002
16	Doxazosin (Cardura)FDA LinkGeneric 01/2019 - 01/2002
14	Biomarkers (Surrogate Marker)IBA 09/2021 - 03/2004
11	Terazosin (Hytrin)FDA LinkGeneric 01/2008 - 01/2002
10	Transforming Growth Factor beta (TGF-beta)IBA 03/2010 - 10/2002
9	Biological ProductsIBA 02/2021 - 10/2002
8	Cadherins (E-Cadherin)IBA 01/2020 - 09/2013
8	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2019 - 03/2004
7	IntegrinsIBA 08/2020 - 02/2004
6	Phosphotransferases (Kinase)IBA 01/2022 - 06/2006
6	taxaneIBA 01/2020 - 11/2014
6	Messenger RNA (mRNA)IBA 01/2020 - 09/2009
6	Androgen Antagonists (Antiandrogens)IBA 01/2020 - 06/2004
6	Pharmaceutical PreparationsIBA 01/2016 - 06/2004
5	Actin Depolymerizing Factors (Cofilins)IBA 12/2017 - 09/2006
4	CytokinesIBA 11/2021 - 02/2009
4	Prostate-Specific Antigen (Semenogelase)IBA 09/2021 - 03/2004
4	MicroRNAs (MicroRNA)IBA 02/2021 - 11/2010
4	enzalutamideIBA 01/2019 - 01/2015
4	Antineoplastic Agents (Antineoplastics)IBA 01/2016 - 12/2007
4	Docetaxel (Taxotere)FDA Link 01/2015 - 10/2010
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2014 - 02/2004
3	CollagenIBA 10/2021 - 03/2003
3	cabazitaxel FDA Link 01/2020 - 02/2016
3	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2019 - 01/2002
3	Fibronectins (Fibronectin)IBA 01/2014 - 03/2003
3	CaspasesIBA 07/2013 - 11/2002
3	Small Interfering RNA (siRNA)IBA 01/2012 - 01/2010
3	Transforming Growth Factor beta1 (TGF beta 1)IBA 02/2008 - 01/2006
2	Protein Kinases (Protein Kinase)IBA 01/2022 - 03/2009
2	Serine Proteases (Serine Protease)IBA 09/2020 - 01/2017
2	KinesinsIBA 01/2020 - 01/2014
2	TetraspaninsIBA 01/2020 - 10/2015
2	Adrenergic Agents (Adrenergic Drugs)IBA 01/2020 - 01/2019
2	Insulin-Like PeptidesIBA 01/2019 - 10/2017
2	VimentinIBA 12/2017 - 11/2016
2	Hormones (Hormone)IBA 07/2016 - 01/2002
2	Epidermal Growth Factor (EGF)IBA 10/2015 - 12/2008
2	Actins (F Actin)IBA 04/2014 - 01/2014
2	TalinIBA 01/2014 - 01/2011
2	TubulinIBA 01/2014 - 10/2010
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2014 - 10/2010
2	Carrier Proteins (Binding Protein)IBA 01/2014 - 06/2006
2	ProhibitinsIBA 01/2010 - 09/2006
2	Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA 09/2009 - 03/2004
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2008 - 03/2003
2	Dihydrotestosterone (Androstanolone)IBA 02/2008 - 10/2002
2	Caspase 3 (Caspase-3)IBA 08/2005 - 05/2002
2	SulfonamidesIBA 03/2003 - 01/2002
2	Tamsulosin (Flomax)FDA LinkGeneric 03/2003 - 01/2002
1	MelatoninIBA 01/2022
1	MAP Kinase Kinase 7IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 11/2021
1	(S)- 2- (3- ((S)- 5- amino- 1- carboxypentyl)ureido)- pentanedioic acidIBA 10/2021
1	AntigensIBA 10/2021
1	Long Noncoding RNAIBA 02/2021
1	NucleosidesIBA 01/2021
1	PseudouridineIBA 01/2021
1	NucleotidesIBA 01/2021
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 10/2020
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 10/2020
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 10/2020
1	AngiotensinsIBA 09/2020
1	VaccinesIBA 09/2020
1	Peptide Hydrolases (Proteases)FDA Link 09/2020
1	Gonadal Steroid Hormones (Sex Hormones)IBA 09/2020
1	2- amino- 3- (4- ((5- amino- 2- phenylbenzo(d)oxazol- 7- yl)methoxy)- 3,5- dichlorophenyl)propanoic acidIBA 01/2020
1	Amino Acid Transport Systems (Amino Acid Transporter)IBA 01/2020
1	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2020
1	LY-2157299IBA 01/2019

Therapy/Procedure

32	Therapeutics 01/2022 - 05/2002
24	Castration 02/2021 - 10/2010
11	Drug Therapy (Chemotherapy) 10/2020 - 10/2010
6	Radiotherapy 01/2020 - 05/2002
3	Prostatectomy (Retropubic Prostatectomy) 07/2020 - 03/2004
2	Treatment Delay 10/2020 - 07/2020
1	Chronotherapy 01/2022
1	Immunotherapy 11/2021